| PLTR |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$1.85B vs. cons $1.814B |
MEDIUM |
| PLTR |
Report |
U.S. Commercial Revenue (Q2 2026) |
BEAT |
pred ~$740M vs. cons $718M |
MEDIUM |
| PLTR |
Report |
Adj. Operating EPS (Q2 2026) |
BEAT |
pred ~$0.40 vs. cons $0.351 |
HIGH |
| PLTR |
Guide |
Q3 2026 Revenue (Q3 2026) |
UNCHANGED |
guide ~$1.96B mid vs. cons ~$1.95B |
HIGH |
| PLTR |
Guide |
FY 2026 Revenue (FY 2026) |
BETTER |
guide ~$7.90B mid vs. cons $7.740B |
MEDIUM |
| PLTR |
Guide |
FY 2026 U.S. Commercial Revenue (FY 2026) |
BETTER |
guide >=3.40B vs. cons $3.221B |
MEDIUM |
| PLTR |
Guide |
FY 2026 Adj. Operating Income (FY 2026) |
BETTER |
guide ~$4.65B mid vs. cons $4.565B |
MEDIUM |
| PLTR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
MEDIUM |
| PLTR |
Return |
5-day cumulative residual |
+7.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY raise drives modest estimate revisions upward; de-rated stock has room to recover; positive day-0 Archetype B quarters consistently followed through |
MEDIUM |